01 10Avodart
Main Therapeutic Indication : Nephrology
Currency : USD
2020 Revenue in Millions : 646
2019 Revenue in Millions : 796
Growth (%) : -19
Main Therapeutic Indication : Nephrology
Currency : USD
2021 Revenue in Millions : 449
2020 Revenue in Millions : 638
Growth (%) : -29
Main Therapeutic Indication : Urology
Currency : USD
2022 Revenue in Millions : 407
2021 Revenue in Millions : 449
Growth (%) : -9
Main Therapeutic Indication : Urology
Currency : USD
2023 Revenue in Millions : 372
2022 Revenue in Millions : 407
Growth (%) : 5
Main Therapeutic Indication : Urology
Currency : USD
2015 Revenue in Millions : 1,143
2014 Revenue in Millions : 933
Growth (%) : -18%
Main Therapeutic Indication : Urology
Currency : USD
2014 Revenue in Millions : -6.10%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Urology
Currency : USD
2016 Revenue in Millions : 787
2015 Revenue in Millions : 815
Growth (%) : -3
Main Therapeutic Indication : Urology
Currency : USD
2017 Revenue in Millions : 864
2016 Revenue in Millions : 895
Growth (%) : -3
Main Therapeutic Indication : Renal Disorders
Currency : USD
2018 Revenue in Millions : 761
2017 Revenue in Millions : 815
Growth (%) : -7%
Main Therapeutic Indication : Nephrology
Currency : USD
2019 Revenue in Millions : 712
2018 Revenue in Millions : 709
Growth (%) : 0
